Already, this genetic mapping and analysis, a key component of the emerging medical specialty known as precision medicine, is being practiced at various academic centers and private specialist doctors' offices. With a trained practitioner and the appropriate diagnostics, you can learn if you have a genetic predisposition to early menopause, for instance, allowing you the chance to decide whether to get pregnant now, or to freeze your eggs. Or if you're in danger of a heart attack, even though you are a triathlete. Or if you have a predisposition to a disease, that in your case can be sparked by stress, giving you the time to explore meditation, if not medication. Read More Obama defiantly pushes agenda in State of the Union This proactive and deeply personalized approach is clearly the future of medicine. But with President Obama's announcement of a new precision medicine Initiative during his State of the Union address, we may see an acceleration of both the funding and availability for this wealth of genetic data. The president gave little detail. He said: "Tonight, I'm launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes and to give all of … Continue reading →

Beverly Hills, California (PRWEB) January 28, 2015 The top orthopedic doctor in Los Angeles and Beverly Hills, Dr. Raj is now offering stem cell procedures for over twenty painful conditions, with new ones including spinal arthritis and degenerative disc disease. The procedures are performed at Beverly Hills Orthopedic Institute and are excellent for offering pain relief and helping patients avoid potentially risky surgery. Call (310) 247-0466 for more information and scheduling. Stem Cell Therapy is now mainstream and Dr. Raj has been a pioneer with it for all types of musculoskeletal indications. This includes procedures for degenerative and rheumatoid arthritis, tendonitis, ligament injury, fractures, soft tissue injuries, wound healing and more. He has performed the procedure on patients who have sports injuries to assist with faster healing and a quicker return to the field, along with those trying to avoid surgery such as a joint replacement or rotator cuff repair. The procedures are outpatient and involve minimal risk to patients. New indications at Beverly Hills Orthopedic Institute include stem cell therapy for spinal arthritis and degenerative disc disease. These are usually very frustrating conditions, as surgery for them can be a roll of the dice. Dr. George Graf, a Double … Continue reading →

Despite enormous progress in cancer therapy, many patients still relapse because their treatment addresses the symptoms of the disease rather than the cause, the so-called stem cells. Work in the group of Veronika Sexl at the University of Veterinary Medicine, Vienna has given a tantalizing clue to a solution. In the current issue of Blood, the scientists report that the cell-cycle kinase CDK6 is required for activation of the stem cells responsible for causing leukemia. Hematopoietic stem cells (HSCs) are normally inactive, i.e. quiescent. When new blood cells are needed, for example to replace blood that has been lost, HSCs start to multiply and develop into mature blood cells. If the process is initiated at an inappropriate time, hematopoietic diseases such as leukemia may result and leukemic stem cells may develop. These represent a major challenge to leukemia therapy: they are quiescent and thus protected from elimination by the immune system and from treatment such as chemotherapy. Leukemic stem cells frequently cause relapse in cancer patients, often years or even decades after an apparently successful treatment. Working with stem cells isolated from mice, Ruth Scheicher and colleagues at the University of Veterinary Medicine, Vienna have investigated possible differences between leukemic … Continue reading →

Regulatory News: NANOBIOTIX (Euronext: NANO ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces the transfer of its shares from compartment C to compartment B of the regulated market of Euronext in Paris with effect as from January 28, 2015, thanks to its stock market capitalization increase performances during 2014. Compartment B groups together listed companies with a stock market capitalization of between 150 million and 1 billion euros. For the record, the average market capitalization of Nanobiotix over the last 60 trading days in 2014 was 249 million euros. This transfer has no impact on the inclusion of Nanobiotix shares to NYSE Euronext indexes. Laurent Levy, CEO of Nanobiotix comments: Following our admission to the SRD label in December, we are proud to announce the transfer of our shares from compartment C to compartment B of the regulated market of Euronext in Paris. This transfer rewards the dynamism and stock market performance of Nanobiotix during 2014. This operation and the strong increase of Nanobiotix shares liquidity with more than 1 billion 300 million euros traded this year, should improve the visibility of Nanobiotix to the international financial and industrial communities. Compartment … Continue reading →

DGAP-News: MagForce AG / Key word(s): Regulatory Admission MagForce AG: MagForce AG and MagForce USA, Inc. Announce FDA Pre-IDE Meeting on MagForce's NanoTherm(TM) Prostate Cancer Therapy Pre-Submission 27.01.2015 / 08:00 --------------------------------------------------------------------- MagForce AG and MagForce USA, Inc. Announce FDA Pre-IDE Meeting on MagForce's NanoTherm(TM) Prostate Cancer Therapy Pre-Submission Berlin, Germany and Nevada, USA, January 27, 2015 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc. today announced that an in-person meeting was held with the U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health to discuss FDA's response to MagForce's NanoTherm(TM) Prostate Cancer Therapy Pre-Submission of November, 2014. "We received very constructive feedback on our submission and have an understanding of the pathway to market in the USA of NanoTherm(TM) Therapy to focally ablate prostate cancer. MagForce USA, Inc. will accelerate the prostate cancer Investigational Device Exemption (IDE) to utilize the MFH 300F NanoActivator(R) for both Glioblastoma and Prostate NanoTherm(TM) Therapy registration," commented Dr. Ben J. Lipps, CEO of MagForce AG and MagForce USA, Inc. About MagForce AG and MagForce USA, Inc. MagForce AG, listed in … Continue reading →